NeuroMetrix reports Q3 revenue $587,314 vs $1.2M last year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2024
0mins
Should l Buy ?
Company Restructuring: The company has made significant changes including strengthening its Board, ending common stock sales, reducing workforce, and phasing out its ADVANCE(R) business, resulting in over $0.5M quarterly savings in operating expenses and cash usage.
Focus on Quell Fibromyalgia: The company is actively promoting its Quell Fibromyalgia product through direct marketing to physicians and sales to Veterans Health Administration facilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
